NMN vs NR: Which NAD+ Precursor Actually Works?

NAD+ declines about 50% between age 40 and 60. That single fact is the foundation of a multi-billion dollar supplement category built around nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Both are precursors to NAD+ — meaning the body uses them as raw material to synthesize NAD+ — and both have been shown in human studies to raise blood NAD+ levels. But they work differently, their evidence bases differ in depth and design, and they are not equally priced.

This guide walks through what each compound is, how it gets converted to NAD+, what the clinical trials actually show, and how to choose between them.

Quick Comparison

What Is NAD+ and Why Does It Decline?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every cell in the body. It participates in hundreds of metabolic reactions, most critically:

• Energy production: NAD+ is essential for the conversion of nutrients to ATP via glycolysis, the citric acid cycle, and the electron transport chain.
• DNA repair: NAD+ is consumed by PARP enzymes, which detect and repair DNA strand breaks.
• Sirtuin activation: Sirtuins — longevity-associated enzymes — require NAD+ as a substrate to regulate gene expression, inflammation, and cellular stress responses.

NAD+ levels drop with age due to increased consumption (more DNA damage, more inflammation) combined with declining biosynthesis. By age 60, most people have roughly half the NAD+ levels they had at 20. Supplementing with NAD+ precursors aims to replenish this deficit.

The Metabolic Pathway

Understanding how NMN and NR convert to NAD+ matters because it shapes their advantages and limitations.

NR’s pathway: NR → (converted to NMN via NRK enzymes) → NMN → (converted to NAD+ via NMNAT enzymes) → NAD+

NMN’s pathway: NMN → (converted to NAD+ via NMNAT enzymes) → NAD+

NMN is one step closer to NAD+ than NR. In tissues with robust NMNAT enzyme activity, NMN may offer a more direct route. However, there is a complication: NMN is a larger molecule than NR, which initially raised questions about whether it could cross cell membranes directly.

Research resolved part of this debate. A 2019 study identified the Slc12a8 transporter — a protein in intestinal cells that can transport NMN directly into the cell without dephosphorylation to NR first. This suggests NMN does not always need to convert to NR before absorption, at least in intestinal tissue. The picture in other tissues is less clear. Gut bacteria also convert both NMN and NR to nicotinic acid (NA), which itself is a potent NAD+ precursor, adding another layer to the metabolic story.

The practical takeaway: both compounds raise NAD+ levels in humans. The mechanistic differences matter more at the research level than at the supplementation level.

Human Clinical Evidence: NR

NR has the longer clinical track record. The landmark pharmacokinetic study by Trammell et al. (2016) demonstrated in 12 healthy adults that single doses of 100 mg, 300 mg, and 1,000 mg of NR safely increased blood NAD+ metabolites in a dose-dependent manner. The study also identified elevated NAAD (nicotinic acid adenine dinucleotide) as a reliable biomarker of effective NAD+ supplementation — a methodological contribution that subsequent NMN trials adopted Trammell et al., 2016.

A subsequent randomized, double-blind, placebo-controlled trial in 140 healthy overweight adults (40–60 years old) found that NIAGEN-brand NR supplementation significantly increased whole-blood NAD+ levels in a dose-dependent manner after two weeks, with no significant adverse events Conze et al., 2019.

A pilot study in 60–80 year-old healthy adults using NR combined with pterostilbene (the Elysium Health “Basis” formulation) showed whole-blood NAD+ increases of 40% at standard dose and 90% at double dose after 4 weeks, with no drug-related adverse events over 8 weeks Airhart et al., 2017.

NR has also been studied for specific conditions:

• Peripheral artery disease: NR supplementation improved six-minute walking distance and treadmill walking time in a small trial
• Cognitive biomarkers: A crossover trial in healthy older adults showed NR at 500 mg twice daily increased NAD+ in neuronal-origin extracellular vesicles and reduced biomarkers of neurodegeneration over 6 weeks

Human Clinical Evidence: NMN

NMN’s human trial database is smaller but expanding. The first notable human study by Irie et al. (2020) found that 100–500 mg/day of NMN was safe and well-tolerated in 10 healthy Japanese men over 12 weeks, with dose-dependent increases in NAD+ metabolites Irie et al., 2020.

The most frequently cited NMN human RCT is Yoshino et al. (2021), a randomized, placebo-controlled trial in 25 premenopausal overweight or obese women. Participants received 250 mg/day of NMN for 10 weeks. NMN increased skeletal muscle NAD+ levels and improved muscle insulin sensitivity — a clinically meaningful metabolic outcome — without adverse events Yoshino et al., 2021.

The highest-profile NMN trial to date is Pencina et al. (2022), which tested MIB-626, a pharmaceutical-grade NMN formulation developed by Metro International Biotech. In 30 healthy middle-aged and older adults, 1,000 mg of MIB-626 twice daily for 28 days more than tripled blood NAD+ levels versus baseline, with excellent tolerability and no serious adverse events Pencina et al., 2022.

A 2023 trial in 80 middle-aged and older adults found NMN supplementation (600 mg/day) enhanced aerobic capacity in amateur runners as measured by VO2max, alongside NAD+ elevation.

Bioavailability Comparison

Both NMN and NR are orally bioavailable. After ingestion, blood NAD+ levels typically begin rising within 1–2 hours and reach peak elevation around 2–4 hours post-dose.

Key differences:

• Molecular size: NR is smaller than NMN and can enter cells via nucleoside transporters without conversion. This makes its cellular uptake broader across tissue types.
• NMN transporter: The intestinal Slc12a8 transporter appears to shuttle NMN directly, but it is not expressed in all tissues. NMN entering circulation from the gut may be dephosphorylated to NR before entering non-intestinal cells.
• Stability: NMN is more chemically stable than NR at room temperature. NR is relatively unstable in the bloodstream, which complicates direct serum measurement.
• Gut microbiome conversion: A growing body of evidence suggests gut bacteria convert both NMN and NR partly to nicotinic acid before they reach the bloodstream. This may mean the NAD+-boosting mechanism for both supplements overlaps more than previously thought.

Dosage

NR: Human trials have used 100–2,000 mg/day. The 250–500 mg/day range appears effective and well-tolerated for most people. EFSA considers NR safe up to 300 mg/day for general adults; this conservative threshold reflects the evidence base available at the time of review, not evidence of toxicity above it.

NMN: Most human trials have used 250–1,200 mg/day. The Yoshino study used 250 mg/day with measurable metabolic effects; the Pencina MIB-626 trial used 2,000 mg/day (1,000 mg twice) with excellent tolerance. For general supplementation, 250–500 mg/day is a reasonable starting point.

There is no direct head-to-head dose-equivalence study between NMN and NR in humans. Based on current trial data, similar NAD+ elevations appear achievable at comparable doses, though this may vary by individual, tissue, and formulation.

Side Effects

Both compounds have strong safety records in clinical trials.

• Neither causes flushing — the niacin (nicotinic acid) flush caused by gram-level doses of niacin is mediated by the GPR109A receptor. NMN and NR do not activate this receptor at supplemental doses.
• Mild gastrointestinal effects (nausea, loose stool) have been reported in some participants at higher doses (>1,000 mg/day) in both categories.
• No serious adverse events have been attributed to either compound in any published human trial.
• Long-term data in humans extends to roughly 12 months for NR and 12 weeks for most NMN studies. Neither has shown safety signals in this timeframe.

One consideration: very high-dose NAD+ precursor supplementation may theoretically favor NAD+ consumption by PARP enzymes (DNA repair) at the expense of other NAD+-dependent processes. This is a theoretical concern, not an observed effect in humans at standard doses.

Regulatory Note on NMN

In late 2022, the FDA issued a decision that NMN is excluded from the dietary supplement definition in the United States because it was authorized for investigation as a new drug (via the MIB-626 IND filing) before being marketed as a supplement. The practical impact of this decision has been inconsistent enforcement — NMN supplements remain widely available — but the regulatory landscape may shift. NR does not face this status and is sold freely as a supplement under GRAS and DSHEA frameworks.

Cost Comparison

NMN is consistently more expensive than NR per equivalent serving, often by 2–4x. The price premium reflects both the compound’s manufacturing complexity and market positioning. For individuals focused on cost-effective NAD+ support, NR offers a more established evidence base at lower cost. For those willing to pay a premium for the growing NMN-specific trial data, the cost difference is the primary downside.

Which Should You Choose?

There is no definitive winner. The honest answer is that both NMN and NR raise NAD+ levels in humans, both are safe at standard doses, and neither has been proven superior to the other in a head-to-head human trial.

NR makes more sense if:

• Cost efficiency matters to you
• You want the longer and more extensive human safety record
• You are starting NAD+ supplementation for the first time
• You prefer a compound with clearer regulatory status

NMN makes more sense if:

• You are specifically targeting metabolic outcomes like muscle insulin sensitivity (the Yoshino trial data is compelling)
• You want the potential advantages of a compound one step closer to NAD+
• You have a practitioner guiding your protocol who prefers NMN

Try either for 60–90 days and assess subjective energy, recovery, and if possible, test whole-blood NAD+ levels before and after. Response variability between individuals is real and not yet well understood.

The Bottom Line

NMN and NR are the two best-studied oral NAD+ precursors. NR has been in human clinical trials longer and has a broader evidence base. NMN’s trial data is catching up rapidly and has shown clinically meaningful metabolic outcomes. Both safely and meaningfully raise NAD+ in humans. The difference in efficacy between them is, at current evidence levels, too small to call definitively. Choose based on cost, regulatory preference, or specific outcomes from the trial literature.

References

1. Trammell et al., 2016 — Nicotinamide riboside is uniquely and orally bioavailable in healthy humans.
2. Conze et al., 2019 — Safety and metabolism of long-term administration of NIAGEN (NR).
3. Airhart et al., 2017 — An open-label, non-randomized study of the pharmacokinetics of NR and its effect on blood NAD+ levels in healthy volunteers.
4. Irie et al., 2020 — Effect of oral administration of NMN on clinical parameters and nicotinamide metabolite levels in healthy Japanese men.
5. Yoshino et al., 2021 — Nicotinamide mononucleotide increases muscle insulin sensitivity in premenopausal women.
6. Pencina et al., 2022 — Efficacy of MIB-626, an oral formulation of β-NMN, on metabolic insulin sensitivity in middle-aged and older adults.
7. Cantó et al., 2012 — The NAD+ precursor NR enhances oxidative metabolism and protects against high-fat diet-induced obesity in mice.
8. Mills et al., 2016 — Long-term administration of NMN mitigates age-associated physiological decline in mice.

Shop WHYZ

WHYZ NMN Powder — Pure pharmaceutical-grade NMN, unflavored, third-party tested. Available on Amazon and WHYZ.com.

Related Guides

• Monk Fruit vs Stevia
• Spirulina vs Chlorella
• Creatine Monohydrate vs HCL